Humacyte Announces Results Of 5-Yr Retrospective Analysis Of Hospital Charges, Payer Costs, And Healthcare Resource Utilization In Patients With Extremity Arterial Injury

- Data is from comprehensive review of hospital charges and all-payer claims over five years - 

- Preventable complications such as amputation and conduit infection increased initial hospital charges by approximately $493,000 and $590,000 per patient respectively –

- Humacyte's Symvess® has consistently demonstrated low rates of infection and high rates of limb salvage –

DURHAM, N.C., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the results of a five-year retrospective analysis of hospital charges, payer costs, and healthcare resource utilization in patients with extremity arterial injury. The average hospital charge for extremity arterial injury repair during initial hospitalization was $316,600 per patient, and amputations and infections increased the average hospital charge per patient by $492,986 and $589,921, respectively. Humacyte's Symvess (acellular tissue engineered vessel) has consistently demonstrated low rates of conduit infection and high rates of limb salvage in the treatment of extremity arterial injury.     

Data from two linked databases (Premier Inc. Healthcare Database and Inovalon all-payer claims database) included hospital charges and reimbursed costs in 964 adult patients with extremity arterial injuries that required surgical repair. Patients undergoing extremity arterial injury repairs using autologous vein, synthetic grafts, and other biological conduits were included, from 2018-2023. All data were collected prior to Food and Drug Administration approval of Symvess for extremity arterial injury repair and so reflect healthcare economics prior to Symvess commercialization. Healthcare costs were analyzed using logit and generalized linear models. 

The extremity arterial injury patient cohort had an average age of 36.5 years, and 26% were treated with conduits other than autologous vein. The average hospital charge for extremity arterial injury repair during initial hospitalization was $316,600, and the average reimbursed cost was $75,947. Preventable complications had enormous impacts on hospital charges, in particular graft infection, amputation, and rhabdomyolysis (severe ischemic damage to muscles). However, incremental reimbursement for these complications was substantially less than the increased hospital charges. Vascular graft infection resulted in an average of $589,921 in additional hospital charges, and the average reimbursed cost was $84,598. Amputation resulted in an average of $492,986 additional hospital charges, and the average reimbursement was $116,611.

Symvess offers an alternative to the high costs of complications from extremity arterial injury that occur when vein is not feasible for repair.  As previously reported in JAMA Surgery, in clinical study Symvess's rate of infection was one-ninth that of synthetic graft historical controls, and Symvess's amputation rate was one-fifth that of historical controls.

Recently published positive three-year results from the V005 Phase 2/3 study of Symvess in extremity arterial injury repair represent the first-ever prospective long-term data in traumatic arterial repair using an off-the-shelf biologic conduit. Extremity arterial injury wounds are challenging for surgeons to treat, and autologous vein grafts have traditionally served as the standard of care due to their durability and low infection rates. However, autologous grafts are not always feasible in trauma settings where veins are damaged or there is little time to harvest - as evidenced by the fact that 26% of reported repairs of such injuries are not performed with vein. Symvess is designed to be immediately available off-the-shelf — saving critical surgical time in emergency situations — and has also consistently demonstrated low rates of infection and high rates of limb salvage.